Florida Takes On Planned Parenthood

In anti-abortion Republicans’ latest attack on abortion pills, Florida’s attorney general is suing Planned Parenthood for allegedly misrepresenting the safety of the drugs-despite the fact that more than 100 scientific studies have shown they are safe and effective. The 37-page lawsuit, announced by Attorney General James Uthmeier’s office on Thursday and filed in Florida’s First [.].

Big Ten releases eye-opening statement on USC football’s fake punt trickery

The Big Ten has finally responded to the controversial fake punt trick play USC executed in Week 11 against Northwestern. As many expected, the conference admitted that the play violated rules and should have been flagged for unsportsmanlike conduct. In an official statement, the Big Ten recognized that the play violated one of the “unfair [.] The post Big Ten releases eye-opening statement on USC football’s fake punt trickery appeared first on ClutchPoints.

Wild video shows Russian chopper pilot make baffling choice before deadly crash

Harrowing video footage shows the moment a Russian helicopter smashed into a pier and bashed its tail off with the pilot then bizarrely choosing to fly out to sea before losing control and crashing. Five senior members of a Russian defense manufacturer were killed in the crash. The dramatic clip reveals a badly botched landing in Russia’s Republic of Dagestan region on Nov. 7 After clipping off its tail, the helicopter then drifts along the Caspian Sea possibly searching for somewhere else to land. Separate CCTV footage reportedly shows the Ka-226 utility copper smashing into a residential building.

George Medicines presents long-term efficacy and safety data for single pill triple combination therapy for hypertension at American Heart Association’s Scientific Sessions 2025

London, UK, Boston, MA, 9 November 2025 George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, today presented long-term efficacy and safety data from a 52-week open-label extension of its pivotal Phase 3 study in treatment-naïve patients with hypertension. In this 52-week follow-up period of 50 subjects, treatment with GMRx2 (US tradename WIDAPLIKTM), demonstrated sustained blood pressure (BP) control out to one year, with good tolerability and low treatment discontinuation.

Sitemap Index